Share this:
January 2018 about us for patients for doctors resources events news

FDA Approves LUTATHERA for Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).  The drug will be used in Peptide Receptor Radionuclide Therapy (PRRT), which is a form of targeted treatment.  LUTATHERA®(lutetium Lu 177 dotatate) is indicated for adult patients with somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors.

Click here to read the FDA press release about the approval 

Click here to read the Advanced Accelerator Applications press release about the approval 

The approval of LUTATHERA® is based on results from the NETTER-1 clinical study. Click here to read the article in the New England Journal of Medicine about the NETTER-1 study. According to carcinoid/NET specialist Dr. Jonathan Strosberg, “The findings were, in my opinion, extraordinarily impressive, the median progression-free survival improved by nearly 80%, which is fairly unprecedented in oncologic studies. The finding is important because limited therapeutic options exist for such patients, who comprise 20% to 45% of neuroendocrine tumor cases.” 

Targeted Radionuclide Therapy
Click here to read more about PRRT from the Society of Nuclear Medicine and Molecular Imaging:

Topics Covered:

♦What is peptide receptor radionuclide therapy (PRRT) and how does it work?

♦What conditions are treated with PRRT?

♦How is PRRT performed?

♦What are the advantages of PRRT?

♦Is PRRT safe?

♦Side effects

♦Home care

Neuroendocrine Tumor Specialist Dr. Jonathan Strosberg on NETTER-1 Clinical Study
The Carcinoid Cancer Foundation's website, support of research, and educational, awareness and advocacy activities are made possible by your contributions. These crucial activities lead towards early detection, improving the quality of life for cancer survivors, and ultimately to a cure. The Carcinoid Cancer Foundation is a 501(c)(3) nonprofit organization. All contributions to The Carcinoid Cancer Foundation are tax-deductible to the extent allowed by law.
                                             THANK YOU for your support!

Carcinoid Cancer Foundation
333 Mamaroneck Avenue #492
White Plains, NY 10605
Phone: 1-888-722-3132

facebook twitter You tube Blog
333 Mamaroneck Ave # 492 | White Plains, NY 10605 US
powered by emma
Subscribe to our email list.